You are here: Industry Insights > HCC

News List

NICE recommends Bayer's Stivarga for advanced hepatocellular carcinoma pharmafile
November 30, 2018
The National Institute for Health and Care Excellence (NICE) has voiced its recommendation for Bayer’s Stivarga (regorafenib) for use on the NHS in England and Wales in the treatment of advanced unresectable hepatocellular carcinoma (HCC)...
Ipsen's Cabometyx gains European approval in hepatocellular carcinoma pharmafile
November 19, 2018
Ipsen’s Cabometyx has received approval from the European Commission for Cabometyx (cabozantinib) as a monotherapy for the treatment of hepatocellular carcinoma
Eisai, Merck get FDA approval for LENVIMA capsules to treat HCC biospectrumasia
August 20, 2018
Marks second approval under Eisai-Merck global collaboration to co-develop and co-commercialize LENVIMA, following Japan in March 2018
Everest Medicines acquires rights to Novartis liver cancer treatment biospectrumasia
June 28, 2018
FGF401 is being evaluated in Phase I/II clinical trials across the U.S., Europe and Asia as a potential new treatment for hepatocellular carcinoma.
Cone beam CT offers detailed imaging for precise RS delivery europeanpharmaceuticalreview
April 26, 2018
A novel technique called radiation segmentectomy (RS), that delivers high doses of radiation to tumours while sparing the surrounding healthy tissue, shows promise as a curative treatment option for patients with early-stage liver cancer, according to a r
Vitamin A derivative selectively kills liver cancer stem cells europeanpharmaceuticalreview
April 26, 2018
Acyclic retinoid, an artificial compound derived from vitamin A, has been found to prevent the recurrence of hepatocellular carcinoma…
Sensitive new assay detects hepatitis B infection in single liver cells and serum europeanpharmaceuticalreview
April 16, 2018
Technique measuring the cccDNA marker may allow earlier detection of hepatocellular carcinoma in patients…
Ipsen Announces EMA Validation of Filing of a New Application for Additional Indication for Cabometyx®, for Patients with Previously Treated Advanced Hepatocellular Carcinoma (HCC) biospace
March 29, 2018
Ipsen today announced that the EMA, the European regulatory authority, has validated the filing of a new application for an additional indication for Cabometyx®, for patients with previously treated advanced Hepatocellular Carcinoma (HCC).
US FDA agrees to review Eisai’s application for Lenvima to treat HCC pharmaceufical-technology
September 29, 2017
Commonly referred to as liver cancer, HCC is currently the second leading cause of cancer-related death.
FDA grants two orphan drug designations for HCC europeanpharmaceuticalreview
August 21, 2017
The FDA has granted two orphan drug designations for T cell therapy products for the treatment of hepatocellular carcinoma…

Previous page 1 2 3 4 Next page